GEMCITABINE AND IRINOTECAN AS FIRST-LINE THERAPY FOR CARCINOMA OF UNKNOWN PRIMARY: RESULTS OF A MULTICENTER PHASE II TRIAL.

Metastatic carcinoma of unknown primary (CUP) has a very poor prognosis, and no standard first-line therapy currently exists.Here, we report the results of a phase II study utilizing a combination of gemcitabine and irinotecan as first-line therapy.Treatment was with gemcitabine 1000 mg/m(2) and irinotecan 75 mg/m(2) weekly times four on a six week

Proteases represent common targets in combating infectious diseases, including COVID-19.The 3-chymotrypsin-like protease (3CLpro) is a validated molecular target for COVID-19, and it is key for developing potent and selective inhibitors for inhibiting viral replication of SARS-CoV-2.In this review, we discuss structural relationships and diverse su